Table 4.
Subsequent analysis of RAVLT test scores in reference to the transition of the trials
| Age Group | Trial | Mean Difference (95% CI) (I-J) | ρ-value | |
| (I) | (J) | |||
| Group 30 | Trial I | Trial II | –2.43 (–3.00, –1.85)* | <0.001 |
| Trial III | –4.25 (–4.93, –3.57)* | <0.001 | ||
| Trial IV | –5.43 (–6.12, –4.73)* | <0.001 | ||
| Trial V | –6.18 (–6.90, –5.46)* | <0.001 | ||
| Trial II | Trial I | 2.43 (1.85, 3.00)* | <0.001 | |
| Trial III | –1.83 (–2.38, –1.27)* | <0.001 | ||
| Trial IV | –3.00 (–3.59, –2.41)* | <0.001 | ||
| Trial V | –3.75 (–4.41, –3.09)* | <0.001 | ||
| Trial III | Trial I | 4.25 (3.57, 4.93)* | <0.001 | |
| Trial II | 1.83 (1.27, 2.38)* | <0.001 | ||
| Trial IV | –1.18 (1.57, –0.78)* | <0.001 | ||
| Trial V | –1.93 (–2.59, –1.26)* | <0.001 | ||
| Trial IV | Trial I | 5.43 (4.73, 6.12)* | <0.001 | |
| Trial II | 3.00 (2.41, 3.59)* | <0.001 | ||
| Trial III | 1.18 (0.78, 1.57)* | <0.001 | ||
| Trial V | –0.75 (–1.41, –0.09)* | 0.027 | ||
| Trial V | Trial I | 6.18 (5.46, 6.90)* | <0.001 | |
| Trial II | 3.75 (3.09, 4.41)* | <0.001 | ||
| Trial III | 1.93 (1.26, 2.59)* | <0.001 | ||
| Trial IV | 0.75 (0.09, 1.41)* | 0.027 | ||
| Group 40 | Trial I | Trial II | –3.35 (–3.92, –2.78)* | <0.001 |
| Trial III | –4.93 (–5.61, –4.24)* | <0.001 | ||
| Trial IV | –6.50 (–7.19, –5.81)* | <0.001 | ||
| Trial V | –7.50 (–8.22, –6.78)* | <0.001 | ||
| Trial II | Trial I | 3.35 (2.78, 3.92)* | <0.001 | |
| Trial III | –1.58 (–2.13, –1.02)* | <0.001 | ||
| Trial IV | –3.15 (–3.74, –2.56)* | <0.001 | ||
| Trial V | –4.15 (–4.81, –3.49)* | <0.001 | ||
| Trial III | Trial I | 4.93 (4.24, 5.61)* | <0.001 | |
| Trial II | 1.58 (1.02, 2.13)* | <0.001 | ||
| Trial IV | –1.58 (–1.97, –1.18)* | <0.001 | ||
| Trial V | –2.58 (–3.24, –1.91)* | <0.001 | ||
| Trial IV | Trial I | 6.50 (5.81, 7.19)* | <0.001 | |
| Trial II | 3.15 (2.56, 3.74)* | <0.001 | ||
| Trial III | 1.58 (1.18, 1.97)* | <0.001 | ||
| Trial V | –1.00 (–1.66, –0.34)* | 0.003 | ||
| Trial V | Trial I | 7.50 (6.78, 8.22)* | <0.001 | |
| Trial II | 4.15 (3.49, 4.81)* | <0.001 | ||
| Trial III | 2.58 (1.91, 3.24)* | <0.001 | ||
| Trial IV | 1.00 (0.34, 1.66)* | 0.003 | ||
| Group 50 | Trial I | Trial II | –3.13 (–3.70, –2.55)* | <0.001 |
| Trial III | –4.23 (–4.91, –3.54)* | <0.001 | ||
| Trial IV | –5.48 (–6.17, –4.78)* | <0.001 | ||
| Trial V | –5.73 (–6.45, –5.01)* | <0.001 | ||
| Trial II | Trial I | 3.13 (2.55, 3.70)* | <0.001 | |
| Trial III | –1.10 (–1.66, –0.54)* | <0.001 | ||
| Trial IV | –2.35 (–2.94, –1.76)* | <0.001 | ||
| Trial V | –2.60 (–3.26, –1.94)* | <0.001 | ||
| Trial III | Trial I | 4.23 (3.54, 4.91)* | <0.001 | |
| Trial II | 1.10 (0.54, 1.66)* | <0.001 | ||
| Trial IV | –1.25 (–1.65, –0.85)* | <0.001 | ||
| Trial V | –1.50 (–2.17, –0.83)* | <0.001 | ||
| Trial IV | Trial I | 5.48 (4.78, 6.17)* | <0.001 | |
| Trial II | 2.35 (1.76, 2.94)* | <0.001 | ||
| Trial III | 1.25 (0.85, 1.65)* | <0.001 | ||
| Trial V | –0.25 (–0.91, 0.41) | 0.457 | ||
| Trial V | Trial I | 5.73 (5.01, 6.45)* | <0.001 | |
| Trial II | 2.60 (1.94, 3.26)* | <0.001 | ||
| Trial III | 1.50 (0.83, 2.17)* | <0.001 | ||
| Trial IV | 0.25 (–0.41, 0.91) | 0.457 | ||
| Group≥60 | Trial I | Trial II | –2.20 (–2.77, –1.63)* | <0.001 |
| Trial III | –4.25 (–4.93, –3.57)* | <0.001 | ||
| Trial IV | –4.85 (–5.54, –4.16)* | <0.001 | ||
| Trial V | –5.48 (–6.20, –4.76)* | <0.001 | ||
| Trial II | Trial I | 2.20 (1.63, 2.77)* | <0.001 | |
| Trial III | –2.05 (–2.61, –1.49)* | <0.001 | ||
| Trial IV | –2.65 (–3.24, –2.06)* | <0.001 | ||
| Trial V | –3.28 (–3.93, –2.62)* | <0.001 | ||
| Trial III | Trial I | 4.25 (3.57, 4.93)* | <0.001 | |
| Trial II | 2.05 (1.49, 2.61)* | <0.001 | ||
| Trial IV | –0.60 (–1.00, –0.20)* | 0.003 | ||
| Trial V | –1.23 (–1.89, –0.56)* | <0.001 | ||
| Trial IV | Trial I | 4.85 (4.16, 5.54)* | <0.001 | |
| Trial II | 2.65 (2.06, 3.24)* | <0.001 | ||
| Trial III | 0.60 (0.20, 1.00)* | 0.003 | ||
| Trial V | –0.63 (–1.29, 0.04)* | 0.064 | ||
| Trial V | Trial I | 5.48 (4.76, 6.20)* | <0.001 | |
| Trial II | 3.28 (2.62, 3.93)* | <0.001 | ||
| Trial III | 1.23 (0.56, 1.89)* | <0.001 | ||
| Trial IV | 0.63 (–0.04, 1.29) | 0.064 | ||
Least significant difference was conducted for the adjustment of multiple comparison. *significant difference (ρ< 0.05) compared to the trials in column (I).